BOTHELL, WA and VANCOUVER, BC, Aug. 10, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Michelle Burris, OncoGenex’ Executive Vice President of Operations and Chief Financial Officer, will be presenting at the 2011 Wedbush Securities Life Sciences Management Access Conference. The OncoGenex corporate presentation will take place on Wednesday, August 17th at 3:35pm ET at Le Parker Meridien Hotel in New York City.
The live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. A webcast replay will be available approximately one hour after the live webcast concludes and will be archived for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex’ lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.
SOURCE OncoGenex Pharmaceuticals, Inc.
